Fiche société
Polina Stepensky
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications2liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| HBI0101 CARTA Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients with B-cell mediated autoimmune disease. | Myasthénie | Phase 1 | Israel | À vérifier | |
| HBI0101 CARTA Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients with B-cell mediated autoimmune disease. | Myasthénie | Phase 1 | Thérapie cellulaire | Israel | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| HBI0101 CART | Myasthénie | Phase 1 | NCT07085676 | Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases | RECRUITING |
Publications
2| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| HBI0101 CART | High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T). | Cancers | ||
| HBI0101 CART | 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders. | Turkish journal of haematology : official journal of Turkish Society of Haematology |